All In Biotech

Drug Trial Radar · NCT05132075

Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

KontRASt-02: A Randomized, Controlled, Open Label, Phase III Study Evaluating the Efficacy and Safety of JDQ443 Versus Docetaxel in Previously Treated Subjects With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC)

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

95

Actual

Start

Jun 15, 2022

Primary completion

Sep 3, 2026

Study completion Oct 5, 2026

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Nov 24, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase III randomized open label study designed to compare JDQ443 as monotherapy to docetaxel in participants with advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation who have been previously treated with a platinum-based chemotherapy and immune checkpoint inhibitor therapy either in sequence or in combination.

Conditions

  • Non-Small Cell Lung Cancer

Interventions

  • JDQ443Drug

    JDQ443 tablets, orally administered

  • docetaxelDrug

    docetaxel concentrated solution for infusion, intravenously administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival (PFS)Time frame: Approximately up to 24 months

Locations

51 sites in 25 countries. Site status is shown where the registry gives one.

  • Valley Medical Center Research

    Renton, Washington

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    Pilar, Buenos Aires, Argentina

  • Novartis Investigative Site

    Auchenflower, Queensland, Australia

  • Novartis Investigative Site

    South Brisbane, Queensland, Australia

  • Novartis Investigative Site

    Montreal, Quebec, Canada

  • Novartis Investigative Site

    Sherbrooke, Quebec, Canada

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Fuzhou, Fujian, China

  • Novartis Investigative Site

    Guangzhou, Guangdong, China

  • Novartis Investigative Site

    Harbin, Heilongjiang, China

  • Novartis Investigative Site

    Changsha, Hunan, China

  • Novartis Investigative Site

    Shengyang, Liaoning, China

  • Novartis Investigative Site

    Jinan, Shandong, China

  • Novartis Investigative Site

    Hangzhou, Zhejiang, China

  • Novartis Investigative Site

    Turku, Finland

  • Novartis Investigative Site

    Athens, Greece

  • Novartis Investigative Site

    Heraklion Crete., Greece

  • Novartis Investigative Site

    Athens, GR, Greece

  • Novartis Investigative Site

    Hong Kong, Hong Kong

  • Novartis Investigative Site

    Kowloon, Hong Kong

  • Novartis Investigative Site

    Budapest, Hungary

  • Novartis Investigative Site

    Reykjavik, Iceland

  • Novartis Investigative Site

    Delhi, India

  • Novartis Investigative Site

    Jaipur, Rajasthan, India

  • Novartis Investigative Site

    Lucca, LU, Italy

  • Novartis Investigative Site

    Aviano, PN, Italy

  • Novartis Investigative Site

    Roma, RM, Italy

  • Novartis Investigative Site

    Amman, Jordan

  • Novartis Investigative Site

    Ed Daoura, Lebanon

  • Novartis Investigative Site

    Kuala Lumpur, Malaysia

  • Novartis Investigative Site

    Kuching, Sarawak, Malaysia

  • Novartis Investigative Site

    Mexico City, Mexico

  • Novartis Investigative Site

    Matosinhos Municipality, Portugal

  • Novartis Investigative Site

    Porto, Portugal

  • Novartis Investigative Site

    Cluj-Napoca, Cluj, Romania

  • Novartis Investigative Site

    Ljubljana, Slovenia, Slovenia

  • Novartis Investigative Site

    Seongnam-si, Gyeonggi-do, South Korea

  • Novartis Investigative Site

    Córdoba, Spain

  • Novartis Investigative Site

    Madrid, Spain

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.